Comparative Pharmacology
Head-to-head clinical analysis: AMRIX versus CYCLOPAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMRIX versus CYCLOPAR.
AMRIX vs CYCLOPAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Centrally acting muscle relaxant; it is the R-enantiomer of baclofen. Agonist at GABA-B receptors in the spinal cord, leading to inhibition of monosynaptic and polysynaptic spinal reflexes, thereby reducing muscle spasticity.
Cyclopar (tetracycline) inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
15 mg orally once daily. May increase to 30 mg once daily if needed, after at least 1 week. Maximum 30 mg/day.
500 mg orally twice daily for 7-14 days.
None Documented
None Documented
Terminal elimination half-life approximately 32 hours (range 28–40 hours); clinically relevant for once-daily dosing in chronic muscle spasm
4-6 hours in normal renal function; prolonged to 12-24 hours in moderate impairment; up to 48 hours in severe impairment
Renal: approximately 40% as unchanged drug and metabolites; biliary/fecal: minimal; total clearance: 2.5 L/min
Renal (80-90% unchanged), fecal (10-20%)
Category C
Category C
Muscle Relaxant
Muscle Relaxant